Last reviewed · How we verify
Staloral TM
Staloral is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through sublingual administration.
Staloral is an allergen immunotherapy tablet that desensitizes the immune system to specific allergens through sublingual administration. Used for Allergic rhinitis and/or allergic asthma caused by grass pollen allergens.
At a glance
| Generic name | Staloral TM |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Allergen immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
Staloral works by gradually exposing the patient to increasing doses of allergen extract under the tongue, which promotes immune tolerance and reduces allergic responses. This sublingual immunotherapy approach shifts the immune response from Th2-mediated (allergic) to Th1-mediated (tolerant) pathways, thereby reducing symptoms upon natural allergen exposure.
Approved indications
- Allergic rhinitis and/or allergic asthma caused by grass pollen allergens
Common side effects
- Oral pruritus
- Throat irritation
- Edema of mouth or throat
- Gastrointestinal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Staloral TM CI brief — competitive landscape report
- Staloral TM updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI